Long-term Care

The Complex Relationship Between Quality Ratings and Pandemic Deaths in Nursing Homes

Yaa Akosa Antwi shares research on nursing home deaths during COVID suggesting even well-intentioned policies can have unintended consequences.

Read More

How Nursing Home Staff Biases Drive Inequitable Care

Jasmine Travers shares research showing how racial biases can impact care for Black nursing home residents with advanced dementia.

Read More

Private Equity’s Impact on Nursing Home Quality

Rachel Werner on new research exploring how nursing homes with private equity investment compared to other nursing homes on cost, outcomes and staffing.

Read More

The Aducanumab Aftermath: The Industry

How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug?

Read More

The Aducanumab Aftermath: The Payer

A costly new Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.

Read More

The Aducanumab Aftermath: The Patient

One patient shares her hopes and concerns about a costly new Alzheimer’s drug.

Read More

The Aducanumab Aftermath

The Aducanumab Aftermath A SPECIAL CONVERSATION SERIES June 22, 2021 Art by Leslie Walker About this Special Series The U.S. Food and Drug Administration (FDA) recently approved the costly new Alzheimer’s drug aducanumab (now known by the brand name Aduhelm) despite doubts about its safety and efficacy. Priced at $56,000 by drugmaker Biogen, aducanumab could…

Read More

The Aducanumab Aftermath: The Doctor

One doctor grapples with questions about a controversial new Alzheimer’s drug’s safety and efficacy.

Read More

The FDA’s Pressure-Packed Alzheimer’s Drug Decision

The FDA weighs whether to approve a controversial new Alzheimer’s drug.

Read More

Biden’s $400 Billion Bet on Caring for Older and Disabled Americans at Home

President Biden wants to make a huge investment in an often neglected part of the health care system.

Read More